Literature DB >> 28721339

The Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Type 2 Diabetes.

Erin St Onge1, Shannon Miller1, Elizabeth Clements2, Lindsay Celauro2, Ke'la Barnes2.   

Abstract

The role of GLP-1 agonists in the treatment of type 2 diabetes have been shown to be viable options for add-on therapy in diabetic patients, as well as potential monotherapy options. With six available GLP-1 agents, and new combination products in the pipeline, they are a promising drug class for type 2 diabetic patients, especially due to their extended dosing interval and potential weight loss benefits.

Entities:  

Keywords:  A1c; GLP-1 receptor agonist; GLP-1RA; glucose; incretin; insulin; type 2 diabetes

Year:  2017        PMID： 28721339      PMCID： PMC5506406          DOI： 10.1515/jtim-2017-0015

Source DB:  PubMed          Journal:  J Transl Int Med        ISSN： 2224-4018


  47 in total

1.  Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.

Authors:  John B Buse; Richard M Bergenstal; Leonard C Glass; Cory R Heilmann; Michelle S Lewis; Anita Y M Kwan; Byron J Hoogwerf; Julio Rosenstock
Journal:  Ann Intern Med       Date:  2010-12-06       Impact factor: 25.391

Review 2.  Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

Authors:  Paul S Jellinger
Journal:  Postgrad Med       Date:  2011-01       Impact factor: 3.840

3.  Exenatide versus glibenclamide in patients with diabetes.

Authors:  G Derosa; P Maffioli; S A T Salvadeo; I Ferrari; P D Ragonesi; F Querci; I G Franzetti; G Gadaleta; L Ciccarelli; M N Piccinni; A D'Angelo; A F G Cicero
Journal:  Diabetes Technol Ther       Date:  2010-03       Impact factor: 6.118

4.  Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

Authors:  Ralph A DeFronzo; Robert E Ratner; Jenny Han; Dennis D Kim; Mark S Fineman; Alain D Baron
Journal:  Diabetes Care       Date:  2005-05       Impact factor: 19.112

5.  Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).

Authors:  Carol Wysham; Thomas Blevins; Richard Arakaki; Gildred Colon; Pedro Garcia; Charles Atisso; Debra Kuhstoss; Mark Lakshmanan
Journal:  Diabetes Care       Date:  2014-05-30       Impact factor: 19.112

6.  Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.

Authors:  Michaela Diamant; Michael A Nauck; Rimma Shaginian; James K Malone; Simon Cleall; Matthew Reaney; Danielle de Vries; Byron J Hoogwerf; Leigh MacConell; Bruce H R Wolffenbuttel
Journal:  Diabetes Care       Date:  2014-07-10       Impact factor: 19.112

7.  HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.

Authors:  Bo Ahrén; Susan L Johnson; Murray Stewart; Deborah T Cirkel; Fred Yang; Caroline Perry; Mark N Feinglos
Journal:  Diabetes Care       Date:  2014-06-04       Impact factor: 19.112

Review 8.  Incretins, insulin secretion and Type 2 diabetes mellitus.

Authors:  T Vilsbøll; J J Holst
Journal:  Diabetologia       Date:  2004-02-13       Impact factor: 10.122

9.  Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study.

Authors:  M J Davies; R Donnelly; A H Barnett; S Jones; C Nicolay; A Kilcoyne
Journal:  Diabetes Obes Metab       Date:  2009-12       Impact factor: 6.577

10.  IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy.

Authors:  Nick Freemantle; Muhammad Mamdani; Tina Vilsbøll; Jens Harald Kongsø; Kajsa Kvist; Stephen C Bain
Journal:  Diabetes Ther       Date:  2015-11-18       Impact factor: 2.945
View more
  2 in total

1.  Small cell lung cancer starting with diabetes mellitus: Two case reports and literature review.

Authors:  Tong Zhou; Yao Wang; Xue Zhao; Yang Liu; Ying-Xuan Wang; Xiao-Kun Gang; Gui-Xia Wang
Journal:  World J Clin Cases       Date:  2019-05-26       Impact factor: 1.337

Review 2.  A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes.

Authors:  Irene Romera; Ana Cebrián-Cuenca; Fernando Álvarez-Guisasola; Fernando Gomez-Peralta; Jesús Reviriego
Journal:  Diabetes Ther       Date:  2018-11-30       Impact factor: 2.945
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.